| 2019 | | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea | 김대중 |
| 2024 | | 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association | 김대중, 김혜진 |
| 2012 | | A compound (DW1182v) protecting high glucose/palmitate-induced glucolipotoxicity to INS-1 beta cells preserves islet integrity and improves hyperglycemia in obese db/db mouse | 강엽, 김대중, 김혜진, 이관우, 한승진 |
| 2024 | | A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | 김혜진 |
| 2018 | | A new comprehensive diabetes health literacy scale: Development and psychometric evaluation | 이관우, 이은현 |
| 2015 | | A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. | 이관우 |
| 2022 | | A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus | 한승진 |
| 2021 | | Antidiabetic effects of betulinic acid mediated by the activation of the AMP-activated protein kinase pathway | 김미란, 장혜진 |
| 2016 | | Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial | 이관우 |
| 2024 | | Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus | 김대중, 전자영 |
| 2020 | | Body mass index and cardiovascular outcomes in patients with acute coronary syndrome by diabetes status: the obesity paradox in a Korean national cohort study | 김대중, 하경화 |
| 1998 | | Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. | 문창현, 정이숙 |
| 2017 | | Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data | 김대중, 하경화 |
| 2018 | | Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study | 김대중 |
| 2016 | | Characterizing treatment pathways at scale using the OHDSI network | 박래웅 |
| 2014 | | Clinical and economic outcomes in medication-adherent and -nonadherent patients with type 2 diabetes mellitus in the Republic of Korea. | 김대중, 김혜진, 이관우, 전기홍, 전자영, 한승진 |
| 2019 | | Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors | 김대중, 전자영 |
| 2005 | | Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. | 황진순 |
| 2016 | | Comparing diabetic patient characteristics related to stated medication adherence in a rural vs. urban community in Korea | 조남한 |
| 2022 | | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study | 김혜진 |
| 2007 | | Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model. | 김대중, 김혜진, 이관우 |
| 2017 | | Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 박래웅, 윤덕용, 이관우, 한승진 |
| 2018 | | Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 이관우, 한승진 |
| 2011 | | Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. | 강엽, 김대중, 김혜진, 이관우, 한승진 |
| 2022 | | Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat | 이성준, 이진수, 조은혜, 홍지만 |
| 2023 | | Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study | 이관우 |
| 2007 | | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. | 김대중, 이관우 |
| 2024 | | Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study | 한승진 |
| 2023 | | Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension | 김혜진 |
| 2017 | | Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) | 이관우 |
| 2024 | | Efficacy and Safety of Metformin and AtorvastatinCombination Therapy vs. Monotherapy with EitherDrug in Type 2 Diabetes Mellitus and DyslipidemiaPatients (ATOMIC): Double-Blinded RandomizedControlled Trial | 김대중 |
| 2024 | | Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial | 김범택 |
| 2019 | | Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial | 이관우 |
| 2023 | | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study | 김대중, 하경화 |
| 2018 | | Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2011 | | Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | 김혜진 |
| 2004 | | Glucose uptake-stimulatory activity of Amomi Semen in 3T3-L1 adipocytes. | 강엽 |
| 2022 | | Healthcare resource utilization in patients treated with empagliflozin in East Asia | 김대중, 하경화 |
| 2000 | | HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. | 김현만, 정윤석 |
| 2019 | | Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study | 이관우 |
| 2020 | | Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study | 김대중, 김혜진, 문소영, 이관우, 전자영, 한승진 |
| 2020 | | Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study (Diabetes Metab J 2020;44:125-33) | 한승진 |
| 2016 | | Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: An analysis based on the Korea National Diabetes Program Cohort | 이관우, 전기홍 |
| 2024 | | Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2020 | | Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism | 이해상, 황진순 |
| 2016 | | Increased postprandial apolipoprotein B-48 level after a test meal in diabetic patients: A multicenter, cross-sectional study | 김대중 |
| 2015 | | Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. | 이관우 |
| 2018 | | Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial | 이관우 |
| 2018 | | Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort | 김대중, 김혜진, 이관우, 전기홍, 전자영, 한승진 |
